BioCorRx (BICX) Receivables (2010 - 2026)

BioCorRx has disclosed Receivables across 17 years of filings, most recently posting $452068.0 for Q1 2026.

• Receivables for Q1 2026 came in at $452068.0, up 70.38% year-over-year; the trailing twelve-month figure through Mar 2026 was $452068.0 (up 70.38% YoY), and the FY2025 annual result was $305485.0, changed N/A from the prior year.
• Receivables came in at $452068.0 for Q1 2026 at BioCorRx, up from $305485.0 in the prior quarter.
• In the past five years, Receivables ranged from a high of $1.1 million in Q2 2022 to a low of $17206.0 in Q3 2023.
• The 5-year median for Receivables is $259065.0 (2022), against an average of $399982.2.
• Across the five-year window, Receivables soared 71598.0% in 2022 and slumped 97.63% in 2023, its largest moves.
• BioCorRx's Receivables stood at $252804.0 in 2022, then plunged by 39.66% to $152532.0 in 2023, then surged by 311.94% to $628340.0 in 2024, then tumbled by 51.38% to $305485.0 in 2025, then soared by 47.98% to $452068.0 in 2026.
• The last three Receivables figures came in at $452068.0 (Q1 2026), $305485.0 (Q4 2025), and $955957.0 (Q3 2025), per Business Quant data.